MTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Pituitary adenomas are the most frequent brain tumor in adults. Although histologically benign, pituitary tumors cause significant morbidity and mortality. Neurosurgery and medical therapeutics may lessen the morbidity and mortality associated with pituitary tumors; however, these treatments are associated with significant adverse side effects. Thus, an improved understanding of pituitary adenomas at the molecular and cellular level is needed to design novel therapeutic compounds. Methods: To assess the effect of mammalian target of rapamycin (mTOR) inhibition on pituitary adenoma cells, rat GH3 or MMQ cells were treated with the clinically useful mTOR inhibitors, rapamycin or RAD001. Cellular proliferation and growth following exposure to mTOR inhibitors or radiation were assessed using biochemical methods. Results: In the present study, we observed basal activation of mTOR, downstream of constitutive Akt signaling, in rat GH3 adenoma cells. Functionally, the mTOR inhibitors, rapamycin and RAD001 (500 pM-5 nM), induced G1 growth arrest within 24 hours, an effect associated with reduced cellular proliferation. Both rapamycin and RAD001 decreased the phosphorylation of mTOR at the serine 2448, a key determinant of mTOR activity. Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone. Conclusions: These data may support a possible therapeutic role for mTOR inhibitors in limiting the cellular proliferation and radioresistance of pituitary adenoma cells.

Original languageEnglish (US)
Article number22
JournalSurgical Neurology International
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Pituitary Neoplasms
Sirolimus
Ionizing Radiation
Cell Proliferation
Morbidity
Mortality
Neurosurgery
Growth
Brain Neoplasms
Adenoma
Serine
Therapeutics
Phosphorylation

Keywords

  • Akt
  • RAD001
  • everolimus
  • mTOR
  • pituitary tumor
  • radiation
  • rapamycin

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

@article{467ff58d709341c78776b59eb3d6e87b,
title = "MTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation",
abstract = "Background: Pituitary adenomas are the most frequent brain tumor in adults. Although histologically benign, pituitary tumors cause significant morbidity and mortality. Neurosurgery and medical therapeutics may lessen the morbidity and mortality associated with pituitary tumors; however, these treatments are associated with significant adverse side effects. Thus, an improved understanding of pituitary adenomas at the molecular and cellular level is needed to design novel therapeutic compounds. Methods: To assess the effect of mammalian target of rapamycin (mTOR) inhibition on pituitary adenoma cells, rat GH3 or MMQ cells were treated with the clinically useful mTOR inhibitors, rapamycin or RAD001. Cellular proliferation and growth following exposure to mTOR inhibitors or radiation were assessed using biochemical methods. Results: In the present study, we observed basal activation of mTOR, downstream of constitutive Akt signaling, in rat GH3 adenoma cells. Functionally, the mTOR inhibitors, rapamycin and RAD001 (500 pM-5 nM), induced G1 growth arrest within 24 hours, an effect associated with reduced cellular proliferation. Both rapamycin and RAD001 decreased the phosphorylation of mTOR at the serine 2448, a key determinant of mTOR activity. Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone. Conclusions: These data may support a possible therapeutic role for mTOR inhibitors in limiting the cellular proliferation and radioresistance of pituitary adenoma cells.",
keywords = "Akt, RAD001, everolimus, mTOR, pituitary tumor, radiation, rapamycin",
author = "{Sukumari Ramesh}, Sangeetha and Nagendra Singh and Dhandapani, {Krishnan Michael} and Vender, {John R}",
year = "2011",
month = "1",
day = "1",
doi = "10.4103/2152-7806.77029",
language = "English (US)",
volume = "2",
journal = "Surgical Neurology International",
issn = "2152-7806",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - MTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation

AU - Sukumari Ramesh, Sangeetha

AU - Singh, Nagendra

AU - Dhandapani, Krishnan Michael

AU - Vender, John R

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Pituitary adenomas are the most frequent brain tumor in adults. Although histologically benign, pituitary tumors cause significant morbidity and mortality. Neurosurgery and medical therapeutics may lessen the morbidity and mortality associated with pituitary tumors; however, these treatments are associated with significant adverse side effects. Thus, an improved understanding of pituitary adenomas at the molecular and cellular level is needed to design novel therapeutic compounds. Methods: To assess the effect of mammalian target of rapamycin (mTOR) inhibition on pituitary adenoma cells, rat GH3 or MMQ cells were treated with the clinically useful mTOR inhibitors, rapamycin or RAD001. Cellular proliferation and growth following exposure to mTOR inhibitors or radiation were assessed using biochemical methods. Results: In the present study, we observed basal activation of mTOR, downstream of constitutive Akt signaling, in rat GH3 adenoma cells. Functionally, the mTOR inhibitors, rapamycin and RAD001 (500 pM-5 nM), induced G1 growth arrest within 24 hours, an effect associated with reduced cellular proliferation. Both rapamycin and RAD001 decreased the phosphorylation of mTOR at the serine 2448, a key determinant of mTOR activity. Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone. Conclusions: These data may support a possible therapeutic role for mTOR inhibitors in limiting the cellular proliferation and radioresistance of pituitary adenoma cells.

AB - Background: Pituitary adenomas are the most frequent brain tumor in adults. Although histologically benign, pituitary tumors cause significant morbidity and mortality. Neurosurgery and medical therapeutics may lessen the morbidity and mortality associated with pituitary tumors; however, these treatments are associated with significant adverse side effects. Thus, an improved understanding of pituitary adenomas at the molecular and cellular level is needed to design novel therapeutic compounds. Methods: To assess the effect of mammalian target of rapamycin (mTOR) inhibition on pituitary adenoma cells, rat GH3 or MMQ cells were treated with the clinically useful mTOR inhibitors, rapamycin or RAD001. Cellular proliferation and growth following exposure to mTOR inhibitors or radiation were assessed using biochemical methods. Results: In the present study, we observed basal activation of mTOR, downstream of constitutive Akt signaling, in rat GH3 adenoma cells. Functionally, the mTOR inhibitors, rapamycin and RAD001 (500 pM-5 nM), induced G1 growth arrest within 24 hours, an effect associated with reduced cellular proliferation. Both rapamycin and RAD001 decreased the phosphorylation of mTOR at the serine 2448, a key determinant of mTOR activity. Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone. Conclusions: These data may support a possible therapeutic role for mTOR inhibitors in limiting the cellular proliferation and radioresistance of pituitary adenoma cells.

KW - Akt

KW - RAD001

KW - everolimus

KW - mTOR

KW - pituitary tumor

KW - radiation

KW - rapamycin

UR - http://www.scopus.com/inward/record.url?scp=79952998207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952998207&partnerID=8YFLogxK

U2 - 10.4103/2152-7806.77029

DO - 10.4103/2152-7806.77029

M3 - Article

VL - 2

JO - Surgical Neurology International

JF - Surgical Neurology International

SN - 2152-7806

IS - 1

M1 - 22

ER -